KRAS and cancer: More recently, it was shown that human bladder and pancreatic cancer cells that harbor oncogenic HRAS or KRAS mutations, respectively, display an enhancement of macropinocytosis relative to cancer cells of the same tissue type that express wild-type HRAS or KRAS (10).